Clinical trial
Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer…
NCT00224068 · Watson Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00224068 |
|---|---|
| Title | Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy |
| Official title | A Multicenter, Randomized, Controlled Prospective Trial of the Safety and Efficacy of Ferrlecit® in Anemic Cancer Patients Who Are Receiving Acute Chemotherapy and Epoetin as Compared to Oral Iron and No Treatment |
| Lead sponsor | Watson Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Anemia |
| Intervention type | Drug |
| Interventions | Sodium ferric gluconate, ferrous sulfate, standard of care |
| Enrollment | 180 |
| Start date | May 1, 2002 |
| Primary completion | Dec 1, 2003 |
| Completion | Dec 1, 2003 |
| First posted | Sep 22, 2005 |
| Last update posted | Mar 2, 2012 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: